REFERENCES
- Blum JL, Jones SE, Buzdar AU, et al. Multicenter, phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485–93.
- Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999; 5: 1696–702.
- Karapetis CS, Patterson WK, Pittman KB, Kotasek D, Sage RE. Treatment of metastatic breast cancer with continuous infu-sional 5-fluorouracil. Aust N Z J Med 1999; 29: 517–22.
- Crivellari D, Magri MD, Buonadonna A, et al. Continuous infusion fluorouracil in the management of advanced breast cancer: a phase II study. Tumori 2000; 86: 42–5.
- Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274–81.
- Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to color-ectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291–7.